Develops and manufactures trauma devices like nails, screws, and plates for fracture fixation. Now — the numbers.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It paid $0.11 per share over the last 12 months, with payments going back years without a break — regular cash for whoever holds the stock.
The stock trades 64% below its five-year peak.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.